Regeneron Pharmaceuticals, headquartered in Tarrytown, New York, focuses on developing medicines for serious diseases, employing 13,450 people. Its key products include EYLEA, Dupixent, and Libtayo, utilizing advanced technologies like VelociSuite.
REGN has been in the news recently: Regeneron Pharmaceuticals Inc. reported a second-quarter adjusted earnings of $12.89 per share, marking a 12% increase from the previous year and surpassing analysts' expectations. Additionally, President Trump has urged 17 pharmaceutical companies, including Regeneron, to reduce U.S. drug prices to "most favored nation" levels by September 29.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
